Market Research Logo

Hepatic Encephalopathy Market - Size, Share, Outlook, and Opportunity Analysis, 2019- 2027

Hepatic Encephalopathy Market - Size, Share, Outlook, and Opportunity Analysis, 2019- 2027

Hepatic encephalopathy (HE) is a common complication of advanced liver disease. HE covers a complex set of non-specific neuropsychiatric symptoms and clinical signs affecting quality of life of patients. HE is a major challenge to the healthcare system due to frequent hospital contacts and admissions. The 2014 AASLD and EASL clinical practice guidelines for managing HE recommend to classify HE according to the underlying liver disease, the severity of the manifestations, the time course, and precipitating factors. HE may be divided into type A that results from acute liver failure, type B that results predominantly from portosystemic encephalopathy (PSS), and type C that results from cirrhosis.

Market Dynamics

HE is a rare disease. Several drugs are available such as antibiotics, laxatives, probiotics, and lactulose that aid in the treatment of this disease. Key players in the market are focused on adopting acquisition strategies to expand their product portfolio. For instance, in December 2017, Mallinckrodt Pharmaceuticals announced acquisition of Ocera Therapeutics, a clinical-stage biopharmaceutical company. Ocera Therapeutics is focused on the development and commercialization of novel therapeutics for orphan and other severe liver diseases.

Hepatic encephalopathy is a syndrome majorly observed in patients suffering from liver cirrhosis, advance liver diseases, and alcohol consumption related cirrhosis. According to the data published in American Liver Foundation in 2017, hepatitis C virus (HCV) infection is the leading cause of liver cirrhosis in the U.S., followed by alcohol consumption related cirrhosis, contributing to around 20% to 25% cases of liver cirrhosis.

Key features of the study:

  • This report provides in-depth analysis of hepatic encephalopathy market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
  • This study also provides key insights into market drivers, restraints, opportunities, hepatic encephalopathy drug approval & launch, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global hepatic encephalopathy market based on the following parameters – company overview, financial performance, drug portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as part of this study include, ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, and Norgine B.V.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future drug launch, manufacturing up-gradation, market expansion, and marketing tactics
  • The global hepatic encephalopathy market report caters to various stakeholders in this industry including investors, suppliers, drug distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the hepatic encephalopathy market
Detailed Segmentation:
  • Global Hepatic Encephalopathy Market, By Drug Class:
  • Antibiotic
  • Laxatives
  • Others
  • Global Hepatic Encephalopathy Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Hepatic Encephalopathy Market, By Region:
  • North America
  • By Country:
  • U.S.
  • Canada
  • By Drug Class:
  • Antibiotic
  • Laxatives
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Europe
  • By Country:
  • Germany
  • France
  • Italy
  • U.K.
  • Spain
  • Russia
  • Rest of Europe
  • By Drug Class:
  • Antibiotic
  • Laxatives
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Asia Pacific
  • By Country:
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia Pacific
  • By Drug Class:
  • Antibiotic
  • Laxatives
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Middle East
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • By Drug Class:
  • Antibiotic
  • Laxatives
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Latin America
  • By Country:
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • By Drug Class:
  • Antibiotic
  • Laxatives
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Africa
  • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
  • By Drug Class:
  • Antibiotic
  • Laxatives
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Company Profiles
  • ASKA Pharmaceutical Co., Ltd.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments
  • Strategies
  • Cosmo Pharmaceuticals N.V.
  • Lupin Limited
  • Kaleido Biosciences
  • Kannalife Sciences, Inc.
  • Bausch Health Companies Inc.
  • Ferring Pharmaceuticals Inc.
  • Mallinckrodt Pharmaceuticals
  • Umecrine Cognition AB
  • Norgine B.V.
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Overview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Class
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Epidemiology
Key Developments
Regulatory Scenario
Reimbursement Scenario
PEST Analysis
4. Global Hepatic Encephalopathy Market, By Drug Class, 2018 - 2026, (US$ Million)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 - 2026
Segment Trends
Antibiotic
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
Laxatives
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
5. Global Hepatic Encephalopathy Market, By Distribution Channel, 2018 - 2026, (US$ Million)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 - 2026
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
6. Global Hepatic Encephalopathy Market, By Region, 2018 - 2026, (US$ Million)
Introduction
Market Share Analysis, By Region, 2018 and 2026 (%)
Y-o-Y Growth Analysis, By Region, 2017 - 2026
North America
Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
U.S.
Canada
Europe
Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
China
Japan
India
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Africa
Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
Market Size and Forecast, By Region/Country, 2018 - 2026, (US$ Million)
North Africa
Central Africa
South Africa
Middle East
Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
GCC Countries
Israel
Rest of Middle East
7. Competitive Landscape
Company Profiles
ASKA Pharmaceutical Co., Ltd.
Company Overview
Source Portfolio
Financial Performance
Recent Developments/Updates
Key Strategies
Cosmo Pharmaceuticals N.V.
Company Overview
Source Portfolio
Financial Performance
Recent Developments/Updates
Key Strategies
Lupin Limited
Company Overview
Source Portfolio
Financial Performance
Recent Developments/Updates
Key Strategies
Kaleido Biosciences
Company Overview
Source Portfolio
Financial Performance
Recent Developments/Updates
Key Strategies
Kannalife Sciences, Inc.
Company Overview
Source Portfolio
Financial Performance
Recent Developments/Updates
Key Strategies
Bausch Health Companies Inc.
Company Overview
Source Portfolio
Financial Performance
Recent Developments/Updates
Key Strategies
Ferring Pharmaceuticals Inc.
Company Overview
Source Portfolio
Financial Performance
Recent Developments/Updates
Key Strategies
Mallinckrodt Pharmaceuticals
Company Overview
Source Portfolio
Financial Performance
Recent Developments/Updates
Key Strategies
Umecrine Cognition AB
Company Overview
Source Portfolio
Financial Performance
Recent Developments/Updates
Key Strategies
Norgine B.V.
Company Overview
Source Portfolio
Financial Performance
Recent Developments/Updates
Key Strategies
8. Section
References
Research Methodology
About us and Sales Contact
*Browse 28 market data tables and 26 figures on "Hepatic Encephalopathy Market - Global forecast to 2026”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook